Evaluation of risperidone in the treatment of behavioral and psychological symptoms and sleep disturbances associated with dementia

Duran, Jose; Greenspan, Andrew; Diago, J.; Gallego, Ricardo; Martinez, G.

doi:10.1017/s104161020500219x

Cited by 18 publications

(12 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been several controlled and open trials that have examined the effectiveness of risperidone for treating BPSD. In an open-label prospective study, Duran et al [13] reported that risperidone treatment was associated with a 63% reduction in the scores on the NPI total scale at week 12, which was lower than our results (76.9%). This discrepancy might be due to differences in the subjects' characteristics, the size of the populations and the treatment periods.…”

Section: Discussioncontrasting

confidence: 99%

Amisulpride versus Risperidone Treatment for Behavioral and Psychological Symptoms in Patients with Dementia of the Alzheimer Type: A Randomized, Open, Prospective Study

Lim¹,

Pae²,

Lee³

et al. 2006

Neuropsychobiology

View full text Add to dashboard Cite

The aim of this study was to evaluate the effectiveness and tolerability of both amisulpride and risperidone for treating the behavioral and psychological symptoms of dementia in patients with dementia of the Alzheimer type (DAT). Twenty-eight patients with DAT were randomly assigned to treatment with either amisulpride or risperidone for 8 weeks. The effectiveness of the treatments was assessed with the Neuropsychiatric Inventory (NPI) and the Clinical Global Impression-Severity of Illness (CGI-S) scale. The Simpson-Angus Rating Scale, the Barnes Akathisia Rating Scale and the Abnormal Involuntary Movement Scale were used for the assessment of side effects. The NPI and CGI-S scores were significantly decreased over time in both treatment groups without any significant group difference and time by treatment group interaction effect (F = 71.85, p < 0.0001). There were no serious adverse events in both groups. This study showed that either amisulpride or risperidone would be effective and tolerable for treating patients with DAT. Adequately powered studies with a head-to-head comparison design will be mandatory to draw any definite conclusion.

show abstract

Section: Discussioncontrasting

confidence: 99%

Amisulpride versus Risperidone Treatment for Behavioral and Psychological Symptoms in Patients with Dementia of the Alzheimer Type: A Randomized, Open, Prospective Study

Lim¹,

Pae²,

Lee³

et al. 2006

Neuropsychobiology

View full text Add to dashboard Cite

show abstract

“…It is noteworthy that risperidone, quetiapine and aripiprazole were the most recommended antipsychotics in the over-mentioned types of dementia. Namely, risperidone had the strongest evidence for the treatment of BPSD symptoms in AD and MixD [60,61,62,63], although it carries higher cardiovascular and metabolic risks.…”

Section: Antipsychotic Use Across Dementia Sub-types (Vad Ad Versmentioning

confidence: 99%

Behavioral Disturbances in Dementia and Beyond: Time for a New Conceptual Frame?

Ambrogio

Martella

Odetti

et al. 2019

IJMS

View full text Add to dashboard Cite

Alzheimer’s disease and vascular dementia are estimated to be the most common causes of dementia, although mixed dementia could represent the most prevalent form of dementia in older adults aged more than 80 years. Behavioral disturbances are common in the natural history of dementia. However, so far, there is a paucity of studies that investigated the causal association between behavioral psychological symptoms of dementia and dementia sub-types, due to the high heterogeneity of methodology, study design and type of clinical assessment. To understand the scant evidence on such a relevant clinical issue, it could be hypothesized that a new shifting paradigm could result in a better identification of the relationship between behavioral disturbances and dementia. This narrative review provides an update of evidence on the behavioral patterns associated with different dementia sub-types and offers a potential future perspective as common ground for the development of new translational studies in the field of behavioral disturbances in dementia and the appropriateness of psychoactive treatments.

show abstract

“…Pharmacological treatments for aggression and related symptoms in dementia include antipsychotics, certain antidepressants, mood stabilizers and other medications. Antipsychotics are the most commonly prescribed drugs for these symptoms and the most effective, at least in the short term , with risperidone being licensed or approved for short‐term treatment of BPSD in Alzheimer's disease in both Canada and the United Kingdom on the basis of several randomized placebo‐controlled trials .…”

Section: Introductionmentioning

confidence: 99%

Gabapentin and pregabalin to treat aggressivity in dementia: a systematic review and illustrative case report

Supasitthumrong

Bolea-Alamañac

Asmer

et al. 2019

Brit J Clinical Pharma

View full text Add to dashboard Cite

AIMSThe prevalence of dementia is rising as life expectancy increases globally. Behavioural and psychological symptoms of dementia (BPSD), including agitation and aggression, are common, presenting a challenge to clinicians and caregivers. METHODSFollowing PRISMA guidelines, we systematically reviewed evidence for gabapentin and pregabalin against BPSD symptoms of agitation or aggression in any dementia, using six databases (Pubmed, CINHL, PsychINFO, HealthStar, Embase, and Web of Science). Complementing this formal systematic review, an illustrative case of a patient with BPSD in mixed Alzheimer's/vascular dementia, who appeared to derive benefits in terms of symptom control and functioning from the introduction of gabapentin titrated up to 3600 mg day À1 alongside other interventions, is presented. RESULTSTwenty-four relevant articles were identified in the systematic review. There were no randomized trials. Fifteen papers were original case series/case reports of patients treated with these compounds, encompassing 87 patients given gabapentin and six given pregabalin. In 12 of 15 papers, drug treatment was effective in the majority of cases. The remaining nine papers were solely reviews, of which two were described as systematic but predated PRISMA guidelines. Preliminary low-grade evidence based on case series and case reviews suggests possible benefit of gabapentin and pregabalin in patients with BPSD in Alzheimer's disease. These benefits cannot be confirmed until well-powered randomized controlled trials are undertaken. Evidence in frontotemporal dementia is lacking. CONCLUSIONGabapentin and pregabalin could be considered for BPSD when medications having stronger evidence bases (risperidone, other antipsychotics, carbamazepine and citalopram) have been ineffective or present unacceptable risks of adverse outcomes.British Journal of Clinical Pharmacology Br J Clin Pharmacol (2019) 85 690-703 690 Gabapentin and pregabalin in dementia treatment Br J Clin Pharmacol (2019) 85 690-703 691 Nomenclature of targets and ligandsKey protein targets and ligands in this article are hyperlinked to corresponding entries in the http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [90], and are permanently archived in the Concise Guide to PHARMA-COLOGY 2017/18 [91].

show abstract

Evaluation of risperidone in the treatment of behavioral and psychological symptoms and sleep disturbances associated with dementia

Abstract: Risperidone is effective and well tolerated in the treatment of BPSD and associated sleep disturbances.

Cited by 18 publications

References 28 publications

Amisulpride versus Risperidone Treatment for Behavioral and Psychological Symptoms in Patients with Dementia of the Alzheimer Type: A Randomized, Open, Prospective Study

Amisulpride versus Risperidone Treatment for Behavioral and Psychological Symptoms in Patients with Dementia of the Alzheimer Type: A Randomized, Open, Prospective Study

Behavioral Disturbances in Dementia and Beyond: Time for a New Conceptual Frame?

Gabapentin and pregabalin to treat aggressivity in dementia: a systematic review and illustrative case report

Contact Info

Product

Resources

About